DexCom, Inc.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$1.26B
↑+13.1% +$146Mvs FY2024 (Q4)
Gross Profit
$793M
↑+20.9% +$137Mvs FY2024 (Q4)
Operating Income
$323M
↑+71.0% +$134Mvs FY2024 (Q4)
Net Income
$267M
↑+76.2% +$116Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $1.26B | $1.11B |
| COGS | $467M | $458M |
| Gross Profit | $793M | $656M |
| R&D | $148M | $140M |
| SG&A | $322M | $327M |
| D&A | $0 | $0 |
| Other OpEx | $0 | $0 |
| Operating Income | $323M | $189M |
| Interest Exp. | $3M | $4M |
| Other Non-Op | $0 | $0 |
| Pretax Income | $320M | $185M |
| Tax | $53M | $34M |
| Net Income | $267M | $152M |
QuarterCharts · SEC EDGAR data · DXCM · Comparing FY2025 (Q4) vs FY2024 (Q4)